BioCentury
ARTICLE | Company News

Fresenius investigating Akorn's alleged breaches of FDA data integrity

March 2, 2018 5:21 PM UTC

In its FY17 earnings report, Fresenius SE & Co. KGaA (Xetra:FRE; OTCQX:FSNUY) said it has engaged external experts to conduct an independent investigation into alleged breaches of FDA data integrity requirements relating to product development at generics company Akorn Inc. (NASDAQ:AKRX). Fresenius' Fresenius Kabi subsidiary agreed to acquire Akorn for $34 per share, or about $4.3 billion, last April (see BioCentury, April 26, 2017). ...